Hand holding the newspaper resting on a table with a cup of coffee

Newsroom

Taxonomy Icon
  • July 28, 2020
The Ivy Brain Tumor Center announced that the first patient has been dosed in an investigator-initiated Phase 0/2 clinical trial of infigratinib in recurrent high-grade glioma driven by FGFR genetic alterations. Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.
Taxonomy Icon
  • July 22, 2020
  • Source: 12 News
Dr. Nader Sanai, director of the Ivy Brain Tumor Center, says although the survival rate is low it doesn't mean there isn't hope to beat cancer. "These are populational statistics, they don't describe you or predict your future." He and Youngblood are teaming up to bring awareness to the disease for Glioblastoma Awareness Day. Sanai says a day focusing on brain cancer is important because it hasn't seen the same progress in therapies like breast or prostate cancer.
Taxonomy Icon
  • July 21, 2020
  • Source: Chamber Business News
Chamber Business News highlights the Ivy Brain Tumor Center's resilience in fighting brain tumors despite the pandemic and the importance of Glioblastoma Awareness Day. Observed as a day to honor those who have been impacted by the disease, the initiative also supports efforts to develop better treatment options that will improve patients’ long-term prognosis.
Taxonomy Icon
  • July 20, 2020
  • Source: azcentral
The Arizona Republic shares the story of Ian Youngblood, a 29-year-old nurse from Arizona who received a harrowing diagnosis of glioblastoma while helping fight COVID-19 on the frontlines in NYC. Dr. Nader Sanai weighs in on why these types of tumors are so hard to control and what it will take to move the needle on identifying new, effective treatment options.
Taxonomy Icon
  • July 17, 2020
Dr. Nader Sanai, director of the Ivy Brain Tumor Center and Ian Youngblood, RN, who was recently diagnosed with a brain tumor, have come together for the second annual Glioblastoma Awareness Day (#GBMDay) on July 22, 2020 to raise national consciousness.
Taxonomy Icon
  • July 10, 2020
  • Source: TODAY Show
Ian's story has moved the country for his strength and selfless service on the COVID-19 frontlines in NYC. Now, facing a battle of his own, he's turning to Dr. Nader Sanai and his team at the Ivy Brain Tumor Center and Barrow Neurological Institute to help him fight one of the most aggressive forms of brain cancer, glioblastoma.
Taxonomy Icon
  • June 24, 2020
The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the appointment of Benjamin Cravatt, Ph.D to its Scientific Advisory Board. Dr. Cravatt is a world-renowned chemical biologist with extensive experience in drug discovery and drug development.
Taxonomy Icon
  • May 28, 2020
  • Source: ABC's The View
On May 27, 2020, Meghan McCain used her national platform to recognize Brain Tumor Awareness Month and her personal connection to this deadly disease on The View. She encourages people to support the Ivy Brain Tumor Center in our mission to cure brain cancer.
Taxonomy Icon
  • May 26, 2020
The Ivy Brain Tumor Center at Barrow Neurological Institute announced that patient recruitment has opened for a Phase 0 clinical trial to evaluate two targeted therapy drugs, abemaciclib and LY3214996. The study will evaluate central nervous system (CNS) penetration in patients with recurrent glioblastoma scheduled for resection. This is the first time a combination of these two drugs will be tested in brain tumor patients.
Taxonomy Icon
  • April 3, 2020
  • Source: Office of Governor Ducey
“It’s very important to me that the medical personnel in this state have the right tools and supplies to fight this battle,” said Catherine Ivy, co-founder of the Ivy Brain Tumor Center.